{"id":68994,"date":"2026-03-12T15:22:39","date_gmt":"2026-03-12T15:22:39","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=68994"},"modified":"2026-05-21T07:14:11","modified_gmt":"2026-05-21T07:14:11","slug":"cjc-1295-with-dac","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/cjc-1295-with-dac\/","title":{"rendered":"CJC-1295 with DAC"},"content":{"rendered":"

<\/p>\n

\n

Rychl\u00e1 odpov\u011b\u010f \u2014 Co je CJC-1295 s DAC?<\/h3>\n

CJC-1295 with DAC<\/strong> je syntetick\u00fd analog hormonu uvol\u0148uj\u00edc\u00edho r\u016fstov\u00fd hormon (GHRH 1-29) modifikovan\u00fd Drug Affinity Complex (DAC)<\/strong> kter\u00fd kovalentn\u011b v\u00e1\u017ee plazmatick\u00fd albumin. Vazba na albumin prodlu\u017euje polo\u010das v plazm\u011b z ~30 minut na p\u0159ibli\u017en\u011b 7 dn\u00ed, co\u017e umo\u017e\u0148uje t\u00fddenn\u00ed nebo dvakr\u00e1t t\u00fddenn\u00ed d\u00e1vkov\u00e1n\u00ed pro v\u00fdzkumn\u00e9 \u00fa\u010dely. Dod\u00e1v\u00e1 se v lyofilizovan\u00fdch vial\u00e1ch o obsahu 2 mg a 5 mg v\u00fdhradn\u011b pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<\/div>\n

Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdzkumn\u00e9 lyofilizovan\u00e9 peptidy \u00b7 HPLC \u010distota \u226599% (COA na vy\u017e\u00e1d\u00e1n\u00ed) \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 p\u0159eprava peptid\u016f \u00b7 1,400+ ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specifikace<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
CAS \u010d\u00edslo<\/strong><\/td>\n863288-34-0<\/td>\n<\/tr>\n
item2<\/strong><\/td>\nC165<\/sub>H269<\/sub>N47<\/sub>O46<\/sub><\/td>\n<\/tr>\n
item7<\/strong><\/td>\n3647.25 Da<\/td>\n<\/tr>\n
item9<\/strong><\/td>\nD-Ala-Tyr-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-NH2<\/sub> konjugovan\u00fd s maleimidopropionyl-Lys (DAC linker pro vazbu na albumin)<\/td>\n<\/tr>\n
item11<\/strong><\/td>\nLyofilizovan\u00fd pr\u00e1\u0161ek (nebo v dodan\u00e9 form\u011b)<\/td>\n<\/tr>\n
item13<\/strong><\/td>\n\u226599% (HPLC ov\u011b\u0159eno, COA na vy\u017e\u00e1d\u00e1n\u00ed)<\/td>\n<\/tr>\n
Skladov\u00e1n\u00ed<\/strong><\/td>\nLyofilizovan\u00e9: 2\u20138 \u00b0C (lednice) pro pracovn\u00ed z\u00e1sobu; \u221220 \u00b0C pro dlouhodob\u00e9 skladov\u00e1n\u00ed neotev\u0159en\u00fdch vialek. Rekonstituovan\u00e9: 2\u20138 \u00b0C, pou\u017eijte do ~30 dn\u016f. Chra\u0148te p\u0159ed sv\u011btlem. Nefreeze\u2013thaw rekonstituovan\u00fd roztok.<\/td>\n<\/tr>\n
Rozpustnost<\/strong><\/td>\nBakteriostatick\u00e1 voda (doporu\u010deno) nebo steriln\u00ed voda pro krat\u0161\u00ed dobu pou\u017eit\u00ed<\/td>\n<\/tr>\n
Pouze pro v\u00fdzkum<\/strong><\/td>\nPouze pro laboratorn\u00ed v\u00fdzkum. Nen\u00ed ur\u010deno pro diagnostick\u00e9 nebo terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed nebo zv\u00ed\u0159at.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Co je CJC-1295 s DAC?<\/h2>\n

CJC-1295<\/strong> je syntetick\u00fd 30-aminokyselinov\u00fd analog hormonu uvol\u0148uj\u00edc\u00edho r\u016fstov\u00fd hormon (GHRH), konkr\u00e9tn\u011b modifikovan\u00e1 forma biologicky aktivn\u00edho fragmentu GHRH (1-29). P\u0159\u00edpona \u201cs DAC<\/strong>\u201d odkazuje na propriet\u00e1rn\u00ed Drug Affinity Complex (DAC)<\/strong> \u2014 zbytek maleimidopropionov\u00e9 kyseliny nav\u00e1zan\u00fd na lysin-30 \u2014 kter\u00fd vytv\u00e1\u0159\u00ed kovalentn\u00ed vazbu s cysteinem-34 s\u00e9rov\u00e9ho albuminu in vivo<\/em>.<\/p>\n

Toto nav\u00e1z\u00e1n\u00ed na albumin je kl\u00ed\u010dovou inovac\u00ed. P\u0159irozen\u00fd GHRH m\u00e1 polo\u010das v plazm\u011b m\u011b\u0159en\u00fd v minut\u00e1ch (rychl\u00e9 odbour\u00e1v\u00e1n\u00ed DPP-IV); CJC-1295 s DAC cirkuluje v\u00e1zan\u00fd na albumin po dobu p\u0159ibli\u017en\u011b 7 dnech<\/strong>, co\u017e umo\u017e\u0148uje t\u00fddenn\u00ed nebo dvakr\u00e1t t\u00fddenn\u00ed v\u00fdzkumn\u00e9 d\u00e1vkov\u00e1n\u00ed p\u0159i udr\u017een\u00ed zv\u00fd\u0161en\u00e9 hladiny GH\/IGF-1 mezi injekcemi. Toto je z\u00e1sadn\u011b odli\u0161n\u00fd farmakokinetick\u00fd profil od verze \u201cbez DAC\u201d (n\u011bkdy naz\u00fdvan\u00e9 Mod GRF 1-29), kter\u00e1 si zachov\u00e1v\u00e1 kr\u00e1tk\u00fd polo\u010das p\u0159irozen\u00e9ho GHRH. Vyvinut\u00fd spole\u010dnost\u00ed ConjuChem, CJC-1295 je ur\u010den pouze pro laboratorn\u00ed v\u00fdzkum<\/strong> a nen\u00ed ur\u010den pro lidskou nebo veterin\u00e1rn\u00ed diagnostiku \u010di terapii. Pro mechanismus, v\u00fdzkumn\u00fd kontext a protokoly kombinov\u00e1n\u00ed viz na\u0161e V\u00fdzkumn\u00fd pr\u016fvodce Ipamorelin & CJC-1295<\/a>.<\/p>\n

Mechanismus \u00fa\u010dinku \u2014 prodlou\u017een\u00e9 p\u016fsoben\u00ed agonist\u016f GHRH<\/h2>\n

CJC-1295 s DAC p\u016fsob\u00ed prost\u0159ednictv\u00edm dvou sekven\u010dn\u00edch mechanism\u016f:<\/p>\n